Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01352793




Registration number
NCT01352793
Ethics application status
Date submitted
11/05/2011
Date registered
12/05/2011
Date last updated
11/03/2015

Titles & IDs
Public title
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Scientific title
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Safety And Tolerability Of A Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rlp2086) Vaccine Given In Healthy Subjects Aged Greater Than Or Equal To 10 To Less Than 26 Years
Secondary ID [1] 0 0
2009-015198-11
Secondary ID [2] 0 0
B1971014
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Meningitis, Meningococcal 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - rLP2086 vaccine
Treatment: Other - control

Experimental: rLP2086 vaccine - rLP2086 vaccine

Other: control - The control treatment will be HAVRIX vaccine at month 0 and 6 and a normal saline injection at month 2.


Treatment: Other: rLP2086 vaccine
120 mcg, 3 doses, at month 0, 2, and 6.

Treatment: Other: control
HAVRIX: 720 EL.U. or 1440 EL.Ul, 2 doses, at month 0 and 6. Placebo: normal saline injection, 1 dose, at month 2.
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With at Least One Serious Adverse Event (SAE) Throughout the Study
Timepoint [1] 0 0
Vaccination 1 up to 6 months after Vaccination 3
Primary outcome [2] 0 0
Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 1
Timepoint [2] 0 0
Within 30 days after Vaccination 1
Primary outcome [3] 0 0
Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 2
Timepoint [3] 0 0
Within 30 days after Vaccination 2
Primary outcome [4] 0 0
Percentage of Participants With at Least One Medically Attended Adverse Event Within 30 Days After Vaccination 3
Timepoint [4] 0 0
Within 30 days after Vaccination 3
Secondary outcome [1] 0 0
Percentage of Participants With at Least One Serious Adverse Event (SAE) During Pre-specified Time Periods
Timepoint [1] 0 0
Within 30 days after Vaccination 1, 2, 3, any vaccination; vaccination phase (Vaccination 1 up to 1 month after Vaccination 3); follow-up phase (1 month up to 6 months after Vaccination 3)
Secondary outcome [2] 0 0
Percentage of Participants With at Least One Medically Attended Adverse Event During Pre-specified Time Periods
Timepoint [2] 0 0
Within 30 days after any vaccination; vaccination phase (Vaccination 1 up to 1 month after Vaccination 3); follow-up phase (1 month up to 6 months after Vaccination 3); throughout study (Vaccination 1 up to 6 months after Vaccination 3)
Secondary outcome [3] 0 0
Percentage of Participants With at Least One Newly Diagnosed Chronic Medical Condition During Pre-specified Time Periods
Timepoint [3] 0 0
Within 30 days after Vaccination 1, 2, 3, any vaccination; vaccination phase(Vaccination 1 up to 1 month after Vaccination 3); follow-up phase(1 month up to 6 months after Vaccination 3); throughout study(Vaccination 1 up to 6 months after Vaccination 3)
Secondary outcome [4] 0 0
Percentage of Participants With at Least One Adverse Event (AE) During Pre-specified Time Periods
Timepoint [4] 0 0
Within 30 days after Vaccination 1, 2, 3, any vaccination; vaccination phase (Vaccination 1 up to 1 month after Vaccination 3)
Secondary outcome [5] 0 0
Percentage of Participants With at Least One Immediate Adverse Event (AE) After Each Study Vaccination
Timepoint [5] 0 0
Within 30 minutes after Vaccination 1, 2, 3
Secondary outcome [6] 0 0
Number of Days Participant Missed School or Work Due to Adverse Events (AEs)
Timepoint [6] 0 0
Vaccination 1 up to 1 month after Vaccination 3

Eligibility
Key inclusion criteria
* Healthy subjects aged 10 to 25 years.
Minimum age
10 Years
Maximum age
25 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Previous vaccination with Hepatitis A virus vaccine
* Previous vaccination with investigational meningococcal B vaccine
* History of culture-proven N. meningitidis serogroup B disease
* Any neuroinflammatory or autoimmune condition
* Any immune defect that would prevent an effective response to the study vaccine

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/09/2014
Sample size
Target
Accrual to date
Final
5715
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA
Recruitment hospital [1] 0 0
Australian Clinical Research Network - Maroubra
Recruitment hospital [2] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [3] 0 0
AusTrials Pty Ltd - Sherwood
Recruitment hospital [4] 0 0
Vaccinology and Immunology Research Trials Unit (VIRTU), Discipline of Paediatrics - North Adelaide
Recruitment hospital [5] 0 0
Telethon Institute for Child Health Research - Subiaco
Recruitment postcode(s) [1] 0 0
2035 - Maroubra
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4075 - Sherwood
Recruitment postcode(s) [4] 0 0
5006 - North Adelaide
Recruitment postcode(s) [5] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Nebraska
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
South Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Utah
Country [16] 0 0
United States of America
State/province [16] 0 0
Virginia
Country [17] 0 0
Chile
State/province [17] 0 0
Araucania
Country [18] 0 0
Chile
State/province [18] 0 0
Region Metropolitana
Country [19] 0 0
Chile
State/province [19] 0 0
Santiago
Country [20] 0 0
Czech Republic
State/province [20] 0 0
Jindrichuv Hradec
Country [21] 0 0
Czech Republic
State/province [21] 0 0
Plzen
Country [22] 0 0
Czech Republic
State/province [22] 0 0
Praha 2
Country [23] 0 0
Czech Republic
State/province [23] 0 0
Tynec nad Sazavou
Country [24] 0 0
Denmark
State/province [24] 0 0
Aarhus N
Country [25] 0 0
Estonia
State/province [25] 0 0
Rakvere
Country [26] 0 0
Estonia
State/province [26] 0 0
Tallinn
Country [27] 0 0
Finland
State/province [27] 0 0
Pori
Country [28] 0 0
Finland
State/province [28] 0 0
Tampere
Country [29] 0 0
Finland
State/province [29] 0 0
Turku
Country [30] 0 0
Germany
State/province [30] 0 0
Hamburg
Country [31] 0 0
Germany
State/province [31] 0 0
Wuerzburg
Country [32] 0 0
Lithuania
State/province [32] 0 0
Kaunas
Country [33] 0 0
Lithuania
State/province [33] 0 0
Vilnius
Country [34] 0 0
Poland
State/province [34] 0 0
Debica
Country [35] 0 0
Poland
State/province [35] 0 0
Krakow
Country [36] 0 0
Poland
State/province [36] 0 0
Lubartow
Country [37] 0 0
Poland
State/province [37] 0 0
Oborniki Slaskie
Country [38] 0 0
Poland
State/province [38] 0 0
Poznan
Country [39] 0 0
Poland
State/province [39] 0 0
Siemianowice Slaskie
Country [40] 0 0
Poland
State/province [40] 0 0
Torun
Country [41] 0 0
Poland
State/province [41] 0 0
Trzebnica
Country [42] 0 0
Poland
State/province [42] 0 0
Wroclaw
Country [43] 0 0
Spain
State/province [43] 0 0
Sevilla
Country [44] 0 0
Spain
State/province [44] 0 0
Valencia
Country [45] 0 0
Sweden
State/province [45] 0 0
SE
Country [46] 0 0
Sweden
State/province [46] 0 0
Umeå

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A multicenter phase 3 safety trial in which 5,700 subjects will be assigned in a 2:1 ratio to receive 120 µg rLP2086 vaccine in a 0, 2, 6 month schedule or control. The control group will receive HAVRIX vaccine at month 0 and 6 and saline at month 2.

All subjects will be followed for 6 months after the last vaccination to assess safety and tolerability.
Trial website
https://clinicaltrials.gov/study/NCT01352793
Trial related presentations / publications
Beeslaar J, Mather S, Absalon J, Eiden JJ, York LJ, Crowther G, Maansson R, Maguire JD, Peyrani P, Perez JL. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 2022 Mar 15;40(12):1872-1878. doi: 10.1016/j.vaccine.2022.01.046. Epub 2022 Feb 11.
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01352793